Clearmind Medicine (NASDAQ: CMND; FSE: CWY0) has announced that it has received final approval from the Hadassah Medical Center, Jerusalem, Israel, for its ongoing, FDA-regulated Phase 1/2a clinical trial evaluating CMND-100—a proprietary MEAI-based oral drug candidate—for the treatment of alcohol use disorder (AUD).
According to Clearmind, this approval will enable Hadassah Medical Center, a leading clinical site in Israel, to join the company’s clinical trial—of which the first cohort treatment was successfully completed—alongside other first-in-class institutions, including Yale School of Medicine’s Department of Psychiatry, Johns Hopkins University School of Medicine and Tel Aviv Sourasky Medical Center, Israel.
The study at Hadassah-University Medical Center will be led by Prof. Joseph Caraco, Director of Clinical Pharmacology Unit in the Department of Medicine.
Clearmind’s clinical trial is a critical step in addressing the global burden of AUD, which accounts for 4.7% of all deaths worldwide, according to WHO. The company anticipates further progress in patient enrollment and data collection across its clinical sites, with the goal of delivering a breakthrough solution for those affected by AUD and their families. The Phase 1/2a clinical trial, a multinational, multi-center study, is designed to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption in patients with AUD.
